Drug Trial Radar · NCT03020602
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Last checked: Nov 19, 2026Latest source record: Aug 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jan 4, 2017
Primary completion
Apr 4, 2019
Study completion Jun 26, 2021
Sponsor
- Lead sponsor
- Seema NagpalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of ubidecarenone injectable nanosuspension (BPM31510) in treating patients with high-grade glioma (anaplastic astrocytoma or glioblastoma) that has come back and have been previously treated with bevacizumab. BPM31510 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions
- Gliosarcoma
- Recurrent Glioblastoma
- Astrocytoma of Brain
- Glioblastoma
Interventions
Laboratory Biomarker AnalysisOther
Correlative studies
Pharmacological StudyOther
Correlative studies
Ubidecarenone Injectable NanosuspensionDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with dose-limiting toxicities defined as thrombocytopenia >= grade 3, hemorrhage >= grade 3, and INR elevation >= grade 2 assessed by CTCAE v4.03Time frame: Up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University, School of Medicine
Palo Alto, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.